1. Academic Validation
  2. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro

  • Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9. doi: 10.1128/AAC.47.10.3123-3129.2003.
Yasuhiro Koh 1 Hirotomo Nakata Kenji Maeda Hiromi Ogata Geoffrey Bilcer Thippeswamy Devasamudram John F Kincaid Peter Boross Yuan-Fang Wang Yunfeng Tie Patra Volarath Laquasha Gaddis Robert W Harrison Irene T Weber Arun K Ghosh Hiroaki Mitsuya
Affiliations

Affiliation

  • 1 Department of Internal Medicine II, Kumamoto University School of Medicine, Kumamoto 860-8556, Japan.
Abstract

We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) Protease inhibitor (PI) containing a 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) and a sulfonamide isostere which is extremely potent against laboratory HIV-1 strains and primary clinical isolates (50% inhibitory concentration [IC(50)], approximately 0.003 micro M; IC(90), approximately 0.009 micro M) with minimal cytotoxicity (50% cytotoxic concentration for CD4(+) MT-2 cells, 74 micro M). UIC-94017 blocked the infectivity and replication of each of HIV-1(NL4-3) variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concentrations up to 5 micro M (IC(50)s, 0.003 to 0.029 micro M), although it was less active against HIV-1(NL4-3) variants selected for resistance to amprenavir (IC(50), 0.22 micro M). UIC-94017 was also potent against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to existing Antiviral regimens after having received a variety of Antiviral agents. Structural analyses revealed that the close contact of UIC-94017 with the main chains of the Protease active-site Amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants. Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections.

Figures
Products